Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079 · View on ClinicalTrials.gov ↗
Study Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Pemetrexed
- DRUG Cetuximab
- DRUG BBO-11818
- DRUG Platinum chemotherapy (cisplatin or carboplatin)
Study Locations (11)
Texas
- Sarah Cannon Research Institute at Mary Crowley — Dallas
- The University of Texas MD Anderson Cancer Center — Houston
- NEXT Oncology — San Antonio
California
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles
- University of California San Diego Moores Cancer Center — San Diego
New York
- NYU Langone Health — New York
- Columbia University Irving Medical Center — New York
Florida
- Moffitt Cancer Center — Tampa
Massachusetts
- Massachusetts General Hospital — Boston
Utah
- Huntsman Cancer Institute — Salt Lake City
Washington
- Fred Hutchinson Cancer Center — Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06917079
The ClinicalTrials.gov registry entry for NCT06917079 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06917079 reports 11 study locations spanning 7 distinct geographic areas — top geographies include Texas, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06917079 about?
NCT06917079 is a clinical study titled "BBO-11818 in Adult Subjects With KRAS Mutant Cancer". A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
What is the current status of trial NCT06917079?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 387 participants. The study started on 2025-03-31. Estimated completion is 2029-09.
What conditions does trial NCT06917079 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Colorectal Cancer (CRC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06917079?
The interventions under investigation include: Pembrolizumab (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG), BBO-11818 (DRUG), Platinum chemotherapy (cisplatin or carboplatin) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06917079?
This trial is sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06917079 being conducted?
This trial has 11 study locations across California, Florida, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.